- Home
- POM vs INMB Comparison
POM vs INMB Comparison
Compare POM & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | POM | INMB |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 36.0M | 34.3M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | POM | INMB |
|---|---|---|
| Price | $0.39 | $1.51 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $5.40 |
| AVG Volume (30 Days) | ★ 1.8M | 237.3K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 11.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $50,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 257.14 |
| 52 Week Low | $0.19 | $1.09 |
| 52 Week High | $6.43 | $11.64 |
Technical Indicators
Market Signals| Indicator | POM | INMB |
|---|---|---|
| Relative Strength Index (RSI) | 53.48 | 60.68 |
| Support Level | $0.21 | $1.40 |
| Resistance Level | $0.43 | $1.71 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 65.36 | 98.31 |
Price Performance
Historical ComparisonAbout POM POMDOCTOR LIMITED American Depositary Shares
Pomdoctor Ltd is an online medical services platform for chronic diseases in China. With a focus on chronic disease management and pharmaceutical services, its business model forms a one-stop platform for medical services, which organically connects patients to doctors and pharmaceutical products. Its experience in tackling chronic diseases can be traced back to the launch of its platform on mobile devices. The company operates in two segments: Internet hospital, and Pharmaceutical supply chain. The majority of revenue is derived from the Pharmaceutical supply chain segment.
About INMB INmune Bio Inc.
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products include INKmune, INBO3, XPro1595, LIVNate, and others.